Bringing Gene Therapies to Market

Published on: 

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

The approval of the first gene therapies and technology advances have spurred research and investment for new treatments and provided hope for patients. Researchers are now talking about “cures” versus “treatments,” says Eric Langer, managing partner, BioPlan Associates, in an interview with BioPharm International. Turning clinical processes into an operational process will prove challenging.

Related Content:

Bio/Pharma BusinessBiologic DrugsManufacturingProcess DevelopmentBiologics APIsDosage FormsEarly Phase DevelopmentFormulation and Drug Delivery, Biologic DrugsManufacturing, Cell TherapiesManufacturing, Biologic DrugsPharmTech Videos
Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35
BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications
Sartorius and Teknova Team Up for Gene Therapy Process Development